Application of indinavir in preparing medicament for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis

A technology for acute respiratory distress and acute lung injury, which is applied in the application field of indinavir in the preparation of drugs for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis, and can solve the pharmacological problems of indinavir. The effect has not been reported and other issues

Inactive Publication Date: 2014-08-13
BINZHOU MEDICAL COLLEGE
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Used alone to treat adult patients who are not clinically suitable for nucleoside or non-nucleoside reverse transcriptase inhibitors, but the pharmacological effects of indinavir in the prevention or treatment of ALI / ARDS and pulmonary fibrosis have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of indinavir in preparing medicament for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis
  • Application of indinavir in preparing medicament for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis
  • Application of indinavir in preparing medicament for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Preparation of Indinavir Sulfate Freeze-Dried Powder for Injection

[0013] Take 50.0g of indinavir sulfate, add 2000ml of water for injection to dissolve it, add 8g of mannitol, stir to dissolve, and ultra-filter to obtain a clear liquid without pyrogen, pour it into a 10ml vial, 2ml / bottle, press the freeze-dried powder Freeze-dried by needle process to make freeze-dried powder injections each containing 50.0 mg of indinavir sulfate.

Embodiment 2

[0014] Example 2 Preparation of Indinavir Sulfate Capsules

[0015] Weigh 100.0g of indinavir sulfate, and 100.0g of carboxymethyl starch sodium, mix well and pass through a 100 mesh sieve, add an appropriate amount of 3% PVP K30 Appropriate amount of water solution to prepare soft material, granulate with 20-mesh sieve, dry at 60°C for 3 hours, sieve with 18-mesh sieve for granulation, add 2.0g of magnesium stearate, mix well and pack into capsules, adjust the weight of the capsules to about 200mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a novel medicinal application of indinavir, and particularly relates to application of indinavir in inhibiting occurrence and development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) and pulmonary fibrosis by inhibiting apoptosis of alveolar epithelial cells and promoting expression of a receptor for advanced glycation endproducts (RAGE) of I-type alveolar epithelial cells to prevent and treat ALI/ARDS and pulmonary fibrosis. In the application, the injection dosage is in a range of 50-2000mg, and preferably 50-1000mg; the oral dosage is in a range of 100-5000mg, and preferably 200-5000mg.

Description

technical field [0001] The present invention relates to that indinavir suppresses the occurrence and development of acute lung injury / acute respiratory distress syndrome (ALI / ARDS) and pulmonary fibrosis so as to prevent or treat ALI / ARDS and pulmonary fibrosis; Type I alveolar epithelial cell apoptosis, promote the expression of receptor for advanced glycation endproducts (RAGE) in type I alveolar epithelial cells, so as to prevent or treat ALI / ARDS and pulmonary fibrosis. Background technique [0002] Acute lung injury / acute respiratory distress syndrome (ALI / ARDS) is a common critical illness with a high mortality rate, which seriously threatens the life of critically ill patients and affects their quality of life. ALI / ARDS is acute hypoxic respiratory function caused by diffuse pulmonary interstitial and alveolar edema caused by damage to pulmonary capillary endothelial cells and alveolar epithelial cells during non-cardiogenic diseases such as severe infection, shock, t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61P11/00
Inventor 蒋王林侯桂革纪云霞吕长俊
Owner BINZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap